DrugDashboards

Zilretta

triamcinolone acetonide extended-release injectable suspension · Kit · Intra-Articular · Pacira Pharmaceuticals, Inc.

NDC 65250-0003-01 · 1 KIT in 1 CARTON * 1 INJECTION, POWDER, FOR SUSPENSION, EXTENDED RELEASE in 1 VIAL, SINGLE-DOSE * 1 INJECTION, SOLUTION in 1 VIAL, SINGLE-DOSE · NDA · View full market →

The short version

Only one company currently supplies this market — there is no backup if it stumbles. Historically, drugs in this position went on to a new shortage within 90 days about 0.5% of the time — roughly 4× the typical drug (0.1%).

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

One drug, every price

The same NDC has different prices depending on who is paying. Units differ between rungs — compare within a rung over time, not rung against rung, unless the units match.

ⓘ How this was built
Data sources
  • CMS NADAC (pharmacy acquisition, weekly)
  • CMS Part B ASP quarterly payment limits
  • CMS Maximum Fair Prices (IRA negotiated, NDC-level)
  • Medicare Part D Spending by Drug (data.cms.gov, name-matched)
  • VA FSS / Big4 federal contract prices (va.gov, twice monthly)
  • ACA Federal Upper Limits + weighted AMP (data.medicaid.gov, monthly)
  • California SB-17 WAC filings (list price, per package)
Method

Each rung is the newest figure for this NDC from one federal price system, shown with its own unit. Part D is matched by drug name because CMS publishes no NDCs there; it is gross spending, before confidential rebates.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

  • Medicare Part B pays (ASP+6%)$19.28per billing unit (1 MG)HCPCS J3304 · Jul 1, 2026
  • Part D plans paid (avg)$644.02per dosage unitgross, before rebates — matched by drug name · 2024
  • Federal ceiling (Big4)$420.95per package of 32MGPacira Therapeutics, Inc. · Jan 1, 2026

Medicare Part D

No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.

How Part D pricing works →

NADAC price per unit

No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.

Estimated fill cost

WAC per package, as filed
$701.24
Reported to Texas DSHS · 2026 annual filing · Pacira Pharmaceuticals, Inc.

Manufacturer list price as filed — not what pharmacies actually pay after discounts.

Medicare Part B (ASP)

Payment limit per 1 MG
$19.280
HCPCS J3304 · Jul 1, 2026 quarter · typically ASP + 6%

Medicaid spend (2025)

$2.2M
6,501 prescriptions paid by Medicaid nationally · all Medicaid spend →

Supply fragility

Not scored — fragility is computed for NADAC-priced NDCs.

90-day shortage risk (model v2)

0.5%chance of a new FDA shortage posting for triamcinolone acetonide (injectable) in the next 90 days

sterile injectable · OAI inspection at a producing facility (24 months) · sole-source market

For scale: the typical drug’s chance is about 0.1% — this one is 4× that.

Backtested statistical model over the whole market, not this package alone. Model details →

Regulatory

Application
NDA208845
TE code
Approval date
Oct 6, 2017
Patents / exclusivity
2 patents, 0 exclusivities
TypeNumber / codeExpires
patent9555048Aug 4, 2031
patent8828440Aug 4, 2031

Shortage history

No FDA shortage reports for this drug or its presentations.

Recalls (this NDC)

  • Class II · OngoingJun 12, 2024
    PACIRA PHARMACEUTICALS INCFailed Dissolution Specifications - did not meet the acceptance criteria for IVR Level 3 testing at 9 months 2-8¿C followed by 6 weeks at 25¿C
  • Class II · OngoingMay 7, 2024
    PACIRA PHARMACEUTICALS INCFailed Stability Specifications - at 12 months 2-8 degrees C followed by 6 weeks at 25 degrees C.

Manufacturers of triamcinolone acetonide extended-release injectable suspension (Kit)

LabelerStrengthFirst seenLast seen
Pacira Pharmaceuticals, Inc.Jul 15, 2026Sep 2, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Zilretta — NDC 65250-0003-01," retrieved September 3, 2026, https://drugdashboards.com/drug/65250000301.

Free to cite with attribution — see how the data is put together.